No Data
No Data
Cibus Announces Proposed Public Offering of Class A Common Stock
Cellectis | 6-K/A: Report of foreign private issuer (related to financial reporting)
Monthly Information on Share Capital and Company Voting Rights
Express News | Cellectis Presents Pre-Clinical Evidence That TALEN-Edited MUC1 CAR T-Cells Reduce Triple-Negative Breast Cancer While Ensuring Safety
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
Cellectis Reveals Promising Cancer Therapy Breakthrough
No Data
No Data